47th week of 2010 patent applcation highlights part 36 |
Patent application number | Title | Published |
20100297198 | LIQUID-TYPE DENTIFRICE COMPOSITION CONTAINED SILVER PARTICLES AND MOUSSE-TYPE DENTIFRICE USING THE SAME - Disclosed are a liquid type dentifrice composition primarily containing silver particles which is drawn out in foam state when used to brush teeth to prevent the liquid dentifrice from flowing down during tooth-brushing, resulting in effective and convenient tooth-brushing function and exhibit bactericidal action and protect mouth and teeth from periodontal disease and other mouth diseases because of original properties of silver ingredients in the dentifrice composition; and, in addition to, a mousse type dentifrice formulation using the same that improves aesthetic property and product quality thereof. The inventive dentifrice composition primarily containing silver particles useful for mouthwash comprises: at least one surfactant selected from a group consisting of 0.5 to 3% by weight of SQdium lauryl sulfate, 0.05 to 1% by weight of sodium sarcosine laurate, 0.5 to 5% by weight of alkyl polyglucoside and 0.5 to 3% by weight of sucrose fatty acid ester; at least one wetting agent selected from a group consisting of 30 to 80% by weight of sorbitol solution and 0.5 to 5% by weight of glycerine; at least one solubilizing agent selected from a group consisting of 0.1 to 1% by weight of hydrogenated polyoxyethylene caster oil and 0.1 to 1% by weight of polyoxyethylene sorbitan monolaurate effective to solubilize flavor and active ingredients; 0.01 to 10% by weight of silver particles with bactericidal action; and the balance of purified water relative to total weight of the composition. The inventive mousse type dentifrice formulation comprising the above liquid dentifrice composition is prepared by steps of: introducing the dentifrice composition comprising silver particles as essential ingredient into a foam generating receptacle with constant capacity; and drawing the composition in foam form through outlet of the receptacle in order to brush teeth. | 2010-11-25 |
20100297199 | NANOEMULSION OF RESVERATROL-PHOSPHOLIPID COMPLEX AND METHOD FOR PREPARING THE SAME AND APPLICATIONS THEREOF - The present invention relates to a nanoemulsion of resveratrol-phospholipid complex, method for preparing the same and applications thereof. The nanoemulsion comprises: 1 part by weight of resveratrol, 2˜30 parts by weight of phospholipid, and 30˜490 parts by weight of an aqueous solution of polyol with the polyol concentration being 30˜99 percent by weight. The method comprises the steps of: a resveratrol-phospholipid complex being prepared, then the complex being dispersed into the aqueous solution of polyol to form a dispersion, and a nanoemulsion with particle size less than 200 nm being formed by homogenization of the dispersion with a high pressure homogenizer or Microfluidizer homogenizer. The nanoemulsion is miscible with water at any ratio, has high stability and high bioavailability, and thus can be widely used for preparation of cosmetics, pharmaceuticals or healthcare products. | 2010-11-25 |
20100297200 | USE OF NITRIC OXIDE TO ENHANCE THE EFFICACY OF SILVER AND OTHER TOPICAL WOUND CARE AGENTS - The present invention is directed to compositions comprising at least one nitric oxide donor and at least one second therapeutically active agent with antimicrobial or wound healing capability. In one embodiment, the nitric oxide donor is a nanoparticle which is designed to control for the amount and duration of release of nitric oxide. The nanoparticle may further comprise the additional therapeutically active agent. The composition is useful for enhancing wound healing and for treating and preventing microbial infection. In one embodiment, the composition is directed toward reducing oral bacteria or dental plaque. The combination of one or more nitric oxide donors and one or more additional therapeutically active agent results in unexpected synergistic effects, wherein both the antimicrobial efficacy of the nitric oxide and the antimicrobial or wound healing efficacy of the second therapeutically active agent are enhanced. As a result, a patient may benefit from reduced dosage requirements and a reduced likelihood of antimicrobial resistance. The composition may be formulated for local or systemic administration, for topical applications as well as for use in coatings for medical supplies and devices. | 2010-11-25 |
20100297201 | Use of Polyelectrolyte Complexes in Antiperspirant Technology - Polyelectrolyte complexes between cationic polymers and anionic polymers are used in antiperspirant compositions containing an active antiperspirant ingredient. | 2010-11-25 |
20100297202 | PLANAR ANTENNA AND METHOD OF MANUFACTURING THE SAME - Disclosed is an aqueous dispersion containing polysaccharide particulate gels, which is characterized by containing particulate gels substantially composed of a polysaccharide. The aqueous dispersion containing polysaccharide particulate gels is also characterized in that shapes of the particulate gels are maintained even after the particulate gels are heated for 30 minutes at 95° C. in an aqueous medium. Namely, disclosed is an aqueous dispersion containing polysaccharide particulate gels, wherein the particulate gels are composed of a polysaccharide and have shapes that can be maintained even after 30-minute heating in an aqueous medium of 95° C. | 2010-11-25 |
20100297203 | IMPACT OF CALCIUM PHOSPHATE COMPLEX ON DENTAL CARIES - The present invention relates to chewing gum and confectionery compositions and methods for reducing dental caries in mammals. In particular, the compositions may include a gum base or carrier, sweetening agents and casein phosphopeptide-calcium phosphate (CPP-ACP). The compositions may be employed to slow the progression and enhance the regression of carious lesions in mammals, particularly in humans. | 2010-11-25 |
20100297204 | PARTICULATE POLYMERS COMPRISING BIOCIDAL ACTIVE SUBSTANCE - The present invention relates to a particulate polymer matrix containing a biocidal active substance, distributed homogeneously in the polymeric matrix, processes for their preparation, dispersions containing this particulate polymer matrix, and their use as a microbiocidal composition for protecting industrial materials. | 2010-11-25 |
20100297205 | PATCH FOR THE EXPULSION OF INSECT POISON FROM THE SKIN AFTER STINGS FROM MEMBRANOUS INSECTS (HYMENOPTERA) - This invention relates to a patch for the expulsion of insect poison from the skin after stings from membranous insects (Hymenoptera). The patch is characterized in comprising a poison-aspirating matrix comprising an expulsion agent as well as a swell layer, which swells after the addition of a liquid through a hole on the top of the patch and thus adds a light pressure to the poison-aspirating matrix towards the skin, whereby a local and relieving effect is achieved. In one embodiment, the matrix further comprises a local anesthetic. The expulsion agent is e.g. a carbohydrate. The swell layer consists e.g. of a silica gel. | 2010-11-25 |
20100297206 | Antimicrobial Upconversion System - Antimicrobial articles, systems, and methods may be used for killing, inactivating, and/or inhibiting microorganisms. The antimicrobial articles and systems utilize up-conversion luminescence wherein a phosphor or luminescent material is capable of absorbing visible, infrared light, or longer wavelength radiation and emitting antimicrobial ultraviolet radiation via upconversion thus inhibiting the growth of, inhibiting the reproduction of or killing or otherwise inactivating microorganisms such as, but not limited to, spores, bacteria, fungi, mildew, mold, and algae. Embodiments of the antimicrobial article or system may comprise such a luminescent material and thus will have antimicrobial activity when exposed to natural or artificial light. | 2010-11-25 |
20100297207 | QUATERNARY AMMONIUM SALTS AS MICROBE INHIBITORS - The present invention relates to quaternary ammonium salts and their use as mold inhibitors. The quaternary salts can be prepared by a chloride ion-promoted reaction between a tertiary amine and an alcohol or polyol in strong acid solution. The quaternary ammonium salts can be applied to a substrate in order to impart anti-mold properties to the substrate. Preferably, the quaternary ammonium salt compounds are applied to paper substrates in an amount of about 1000 ppm. Preferably, the quaternary ammonium salts compounds are applied as mixtures of more than one quaternary ammonium salt compound. The treated substrate does not require encapsulators, binders, or retention aids. | 2010-11-25 |
20100297208 | SCAFFOLD - The present invention relates to scaffolds which can be used as medical devices for guided tissue regeneration and repair, in particular the invention is directed to a scaffold comprising fibres having a mean fibre diameter of between from about 1.2 to 4.0 microns, wherein the fibres comprise a glycolide. The invention further relates to the use of the scaffolds for the selective capture of cell populations for a cell source material. | 2010-11-25 |
20100297209 | SOLVENT/POLYMER SOLUTIONS AS SUSPENSION VEHICLES - A nonaqueous, single-phase vehicle that is capable of suspending an active agent. The nonaqueous, single-phase vehicle includes at least one solvent and at least one polymer and is formulated to exhibit phase separation upon contact with an aqueous environment. The at least one solvent may be selected from the group consisting of benzyl benzoate, decanol, ethyl hexyl lactate, and mixtures thereof and the at least one polymer may be selected from the group consisting of a polyester, pyrrolidone, ester of an unsaturated alcohol, ether of an unsaturated alcohol, polyoxyethylenepolyoxypropylene block copolymer, and mixtures thereof. In one embodiment, the at least one solvent is benzyl benzoate and the at least one polymer is polyvinylpyrrolidone. A stable, nonaqueous suspension formulation that includes the nonaqueous, single-phase vehicle and an active agent, and a method of forming the same, are also disclosed. | 2010-11-25 |
20100297210 | REPAIR AND TREATMENT OF BONE DEFECT USING AGENT PRODUCED BY CHONDROCYTES CAPABLE OF HYPERTROPHICATION AND SCAFFOLD - The present invention provides a composite material for promoting or inducing osteogenesis in a biological organism. The composite material includes: A) an induced osteoblast differentiation inducing agent obtained by culturing chondrocytes capable of hypertrophication in a differentiation agent producing medium containing dexamethasone, β-glycerophosphate, ascorbic acid and a serum component; and B) a biocompatible scaffold. The present invention also provides a method of producing this composite material and a method of promoting or inducing osteogenesis in a biological organism. | 2010-11-25 |
20100297211 | BIOBENEFICIAL POLYAMIDE/POLYETHYLENE GLYCOL POLYMERS FOR USE WITH DRUG ELUTING STENTS - This disclosure provides a medical device and a method of forming the medical device. The medical device comprises a coating comprising a type-one polymer and a type-two polymer. The type-one polymer comprises at least two different blocks, at least one L1 block with the formula | 2010-11-25 |
20100297212 | SCAFFOLD FOR CELL GROWTH AND DIFFERENTIATION - The present invention provides a devitalized mammalian parenchymatous tissue composition which includes an interstitial structure which can serve as a scaffold for tissue repair or regeneration. The devitalized mammalian parenchymatous tissue composition can further include the basement membrane of the tissue. | 2010-11-25 |
20100297213 | Method For Making Patches By Electrospray - The invention relates to patches and methods for manufacturing patches intended for skin application of a substance wherein the patch includes a conductive support, and a liquid formulation of the substance is deposited on the support of the patch by electrohydrodynamic spraying. | 2010-11-25 |
20100297214 | PERCOLATIVE DRYING FOR THE PREPARATION OF PARTICLES - The present invention relates to dry particles and methods of preparing the same, in particular to methods of producing dry particles comprising a thermally labile component such as a colloidal system or a thermally labile biopharmaceutical compound, to the use of such dry particles, and to pharmaceutical compositions comprising the same. | 2010-11-25 |
20100297215 | COMPOSITIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY - Compositions, pharmaceutical preparations and methods are disclosed for protecting non-neoplastic cells from damage caused by cancer chemotherapeutic agents or radiation therapy, during the course of cancer therapy or bone marrow transplant. These are based on the use of chemoprotective inducing agents that induce or increase production of cellular detoxification enzymes in target cell populations. The compositions and methods are useful to reduce or prevent hair loss, gastrointestinal distress and lesions of the skin and oral mucosa that commonly occur in patients undergoing cancer therapy. Also disclosed is a novel assay system for identifying new chemoprotective inducing agents. | 2010-11-25 |
20100297216 | METHOD FOR ADMINISTRATION OF PEGYLATED LIPOSOMAL DOXORUBICIN - An embodiment of the present invention comprises a method of treating malignancies in a subject in need of treatment comprising administering to the subject a high loading dose of a pegylated liposomal doxorubicin (PLD) in an initial cycle, followed by a reduced dose in a second cycle, wherein the second cycle reduced dose is in the range of 20% to 50%, preferably 50%, of the initial loading dose, and thereafter one or more maintenance doses in further cycles. The interval between dose cycles is in the range of about three-to-four weeks, preferably about four weeks. The initial loading dose is in the range of between the maximum tolerated dose (MTD) and the recommended dose, preferably the MTD (for instance, in the range of about 70 mg/m2 to 50 mg/m2, preferably 60 mg/m2). The one or more maintenance doses are in the range of about 40 mg/m2 to 50 mg/m2, preferably 45 mg/m2). | 2010-11-25 |
20100297217 | ISOPRENOID COMPOUNDS, THEIR ISOLATION AND USE - There is provided an isoprenoid according to the general formula (I) wherein R | 2010-11-25 |
20100297218 | TISSUE ADHESIVE COMPOSITIONS AND METHODS THEREOF - The present invention relates to composition and method for an adhesive composition. In particular, the present invention relates to a composition of an adhesive composition containing a protein component and an aldehyde component where the aldehyde component further comprises of a thickening agent. The adhesive composition is used for adhering to a tissue in various applications. The adhesive composition can be used for marking a location within the human body, such as a tumor. | 2010-11-25 |
20100297219 | Methods and Compositions for Modifying Apolipoprotein B mRNA Editing - Products and methods for modifying apolipoprotein B mRNA editing in vivo, reducing serum LDL levels, and treating or preventing an atherogenic disease or disorder are disclosed. Such methods involve the use of a protein including APOBEC-1 or fragments thereof which can edit mRNA encoding apolipoprotein B. The protein including APOBEC-1 can be taken up by cells in the form of a delivery vehicle, such as a liposome or niosome, or directly as a chimeric protein which includes a first polypeptide that includes a protein transduction domain and a second polypeptide that includes APOBEC-1 or a fragment thereof which can edit mRNA encoding apolipoprotein B. | 2010-11-25 |
20100297220 | Pharmaceutical Formulation And Method For Treating Acid-Caused Gastrointestinal Disorders - Pharmaceutical formulations in the form of a powder for suspension comprising at least one proton pump inhibitor in micronized form; at least one antacid; and at lest one suspending agents are provided herein. Also provided herein are methods for making and using pharmaceutical formulations comprising at least one proton pump inhibitor and at least one antacid. | 2010-11-25 |
20100297221 | PHARMACEUTICAL COMPOSITION OF TACROLIMUS - An oral tacrolimus composition comprises minicapsules having a core containing tacrolimus in a solubilised liquid form. The minicapsules have a release profile to release the pre-solubilised tacrolimus throughout the entire gastrointestinal tract. The composition may be used, for example, for treatment or prevention of solid organ transplant rejection. | 2010-11-25 |
20100297222 | METHOD FOR PRODUCTION OF MICROCAPSULES USING SOLID FAT - A method for production of fine microcapsules which encapsulate a hydrophilic bioactive substance at a high content and can be used in wide range of applications such as foods and medical drugs, which method enabling efficient industrial production, is provided. A method for production of S/O type microcapsules including the steps of: (1) emulsifying and dispersing a mixture of a solid fat and an aqueous solution containing a hydrophilic bioactive substance at a temperature of at least the melting point of the solid fat to obtain a W/O emulsion; (2) removing moisture in the W/O emulsion at a temperature of at least the melting point and lower than the boiling point of the solid fat to obtain an S/O suspension; (3) adding the S/O suspension into an aqueous phase containing at least one selected from a surfactant (B), a thickening agent and a hydrophilic organic solvent, and permitting liquid droplet dispersion at a temperature of at least the melting point and lower than the boiling point of the solid fat to obtain an S/O/W emulsion; and (4) cooling the S/O/W emulsion to lower than the melting point of the solid fat to harden the solid fat, and further removing the moisture at a temperature lower than the melting point of the solid fat. | 2010-11-25 |
20100297223 | PHARMACEUTICAL DOSAGE FORM COMPRISING A LIQUID OR FLOWABLE CORE COMPOSITION - A pharmaceutical dosage form, comprising a) a liquid or flowable core, b) a shell of a polysaccharide or proteinaceous material completely enclosing said core, the core comprising an active ingredient dissolved in a pharmaceutically acceptable compound of the formula (I) wherein n is an integer from 3 to 5, and wherein the (i) the at least one active ingredient and the compound of the formula (I) account for at least 50% by weight of the composition; and (ii) the water activity aw of the composition is less than 0.4. | 2010-11-25 |
20100297224 | NSAID Dose Unit Formulations with H2-Receptor Antagonists and Methods of Use - The present invention generally relates to pharmaceutical unit dosage forms of NSAIDs and H2-receptor antagonists, in which the H | 2010-11-25 |
20100297225 | SUSTAINED-RELEASE PHARMACEUTICAL FORMULATION CONTAINING AN ANTIMUSCARINIC AGENT AND A WETTING AGENT AS WELL AS A PROCESS FOR THE PREPARATION THEREOF - The present invention relates to improved sustained release dosage forms such as tablets and capsules, and in particular to a pharmaceutical formulation for oral administration comprising a therapeutically effective quantity of an antimuscarinic agent, such as Tolterodine or pharmaceutical acceptable salt, derivative, prodrug and metabolite thereof in combination with a wetting agent, such as Sodium Docusate to improve the release of the active ingredient and a method for the preparation thereof. | 2010-11-25 |
20100297226 | MULTIPLE UNIT PHARMACEUTICAL FORMULATION - An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a MUPS tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating. The individual units are preferably at least partially coated with an outer coating which features a stress absorber, thereby enabling the pellets to be compressed without disturbing the integrity of the enteric coating. The enteric coating preferably does not feature a plasticizer. | 2010-11-25 |
20100297227 | PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE ACTIVE AGENT AND A BINDER, WHICH SWELLS IN AN ACIDIC MEDIA - The invention relates to a pharmaceutical composition, which comprises at least one active agent and which further comprises a binder and/or a retarding agent, wherein the binder swells in an acidic medium, and the retarding agent retards the release of the active agent in an acidic or alkaline medium. | 2010-11-25 |
20100297228 | UNIVERSAL COATING FOR IMPRINTING IDENTIFICATION FEATURES - To improve anticounterfeiting protection, a method for imprinting pharmaceutical unit compositions comprising: providing a pharmaceutical unit composition, partially coating the exterior of the composition with a coating, stamping the coating with a stamp comprising a plurality of identification features, wherein identification features from the stamp are at least partially transposed in the coating and form a barcode, wherein the plurality of identification features comprise at least one lateral dimension of about 1,000 nm or less. Other objects can be coated and stamped including currency and luxury goods. | 2010-11-25 |
20100297229 | TAPENTADOL COMPOSITIONS - The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release Tapentadol Hydrochloride and therapeutically effective amount of a second analgesic, wherein the second analgesic is tramadol, gamma-aminobutyric acid (GABA) analogue or an NSAID. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a slow release Tapentadol Hydrochloride and a therapeutically effective amount of a second analgesic, wherein the second analgesic is tramadol, gamma-aminobutyric acid (GABA) analogue or an NSAID. | 2010-11-25 |
20100297230 | COMPOSITIONS AND METHODS FOR PROSTATE AND MENSTRUAL/MENOPAUSAL RELATED HEALTH - The disclosure provides compositions and methods and maintaining prostate health and relieving menstrual and menopausal related symptoms. The compositions comprise at least two of an icariin component, a quercetin component, a Maca component, a cocoa polyphenols component, and/or a rosmarinic acid component. | 2010-11-25 |
20100297231 | PRESERVATION OF BIOACTIVE MATERIALS BY FREEZE DRIED FOAM - This invention provides methods, systems and compositions to preserve bioactive materials in a dried foam matrix. Methods provide non-boiling foam generation and penetration of preservative agents at temperatures near the phase transition temperature of the membranes. Bioactive materials can be preserved with high initial viability in a freeze-foam process employing low temperature secondary drying. | 2010-11-25 |
20100297232 | ONDANSETRON FILM COMPOSITIONS - The present invention relates to products and methods of making products having a taste masked active component. In particular, the present invention relates to taste-masked film dosage forms including at least one active component and a slow dissolving basic composition. | 2010-11-25 |
20100297233 | OSCILLATING CELL CULTURE BIOREACTOR - Methods and devices for cell or tissue culture are provided. One aspect provides a bioreactor having a gas permeable, closed-loop chamber for cell or tissue culture, and an oscillating means for moving the gas permeable, closed-loop chamber bidirectionally along an axis horizontal to an axis normal to the closed-loop chamber to force convection of cells and fluid in the gas permeable, closed-loop chamber. The bioreactor optionally includes a tissue engineering scaffold, an inlet means, an outlet means, and integrated sensors. Another aspect provides a bioreactor having a plurality of gas permeable, closed-loop chambers for cell or tissue culture. Methods of culturing cells and producing tissue constructs are also provided. | 2010-11-25 |
20100297234 | METHOD OF USING AN EXTRACELLULAR MATRIX TO ENHANCE CELL TRANSPLANT SURVIVAL AND DIFFERENTIATION - Provided is a matrix for promoting survival and differentiation of cells transplanted thereon, comprising a base matrix and a cell-made matrix thereon. Methods and means for making and using same are also provided. | 2010-11-25 |
20100297235 | Vascular puncture closure systems, devices, and methods using biocompatible synthetic hydrogel compositions - A hydrogel composition for application to vascular puncture site of an animal to arrest bleeding and promote hemostasis mixes a biocompatible, synthetic, electrophilic polymer component comprising a poly(ethylene glycol) (PEG) Succinimidyl Glutarate having a functionality of four and a molecular weight of about 10,000 g/mole, with a biocompatible, synthetic, nucleophilic polymer component comprising a blend of a poly(ethylene glycol) (PEG) Amine having a functionality of four and a molecular weight of about 10,000 g/mole, and a Poly-L-Lysine hydrobromide having a molecular weight of greater than about 8000 g/mole. | 2010-11-25 |
20100297236 | HYBRID INDUCIBLE RELEASE VEHICLE - The invention is directed to a hybrid inducible release vehicle, to a method for preparing such a vehicle, and to the use thereof. | 2010-11-25 |
20100297237 | NANOPARTICLES COMPRISING A NON-IONIZABLE POLYMER AND AN AMINE-FUNCTIONALIZED METHACRYLATE COPOLYMER - A pharmaceutical composition comprises nanoparticles comprising a poorly water soluble drug, a poorly aqueous soluble non-ionizable polymer, and an amine-functionalized methacrylate copolymer. | 2010-11-25 |
20100297238 | Multifunctional and Biologically Active Matrices from Multicomponent Polymeric Solutions - A functionalized electrospun matrix for the controlled-release of biologically active agents, such as growth factors, is presented. The functionalized matrix comprises a matrix polymer, a compatibilizing polymer and a biomolecule or other small functioning molecule. In certain aspects the electrospun polymer fibers comprise at least one biologically active molecule functionalized with low molecular weight heparin. | 2010-11-25 |
20100297239 | OSSEOINTEGRATIVE MENISCUS AND CARTILAGE IMPLANTS BASED ON BETA-GLUCAN NANOCOMPOSITES - The present invention provides engineered composite materials for use in medical treatment of injured or degenerated menisci, cartilage, and bone. The composite materials include a cellulosic layer substantially or completely consisting of β-1→4-glucan units, and a hydrogel layer substantially or completely consisting of copolymers of β-1→2-glucan, β-1→3-glucan, and/or β-1→4-glucan, or mixtures of two or all three of these units. Production of the composite materials is achieved in a single culture milieu, using regulation of oxygen availability to control production of the various units and deposition of the layers by | 2010-11-25 |
20100297240 | 1- [2- (2,4-DIMETHYLPHENYLSULFANYL)-PHENYL] PIPERAZINE AS A COMPOUND WITH COMBINED SEROTONIN REUPTAKE, 5-HT3 AND 5-HT1A ACTIVITY FOR THE TREATMENT OF COGNITIVE IMPAIRMENT - 1-[2-(2,4-dimethylphenylsulphanyl)phenyl]piperazine exhibits potent activity on SERT, 5-HT | 2010-11-25 |
20100297241 | Amorphous Fesoterodine Fumarate - The present invention provides a novel amorphous form of fesoterodine fumarate, process for preparation, pharmaceutical compositions, and method of treating thereof. | 2010-11-25 |
20100297242 | LDL-LIKE CATIONIC NANOPARTICLES FOR DELIVERYING NUCLEIC ACID GENE, METHOD FOR PREPARING THEREOF AND METHOD FOR DELIVERYING NUCLEIC ACID GENE USING THE SAME - Disclosed are a LDL-like cationic nanoparticle for delivering a nucleic acid gene with improved transfection efficiency and stability, which is surface modified and re-constructed by mimicking lipid components of a natural LDL, a method for preparation of the same, and a method for delivering nucleic acid genes using the same. The cationic nanoparticle of the present invention could effectively be applied in treatment of cancer that overexpress LDL receptors. | 2010-11-25 |
20100297243 | PRION FREE NANOPARTICLE COMPOSITIONS AND METHODS OF MAKING THEREOF - The present invention provides prion-free compositions comprising nanoparticles comprising albumin and substantially water insoluble drugs. Also provided are methods of making prion-free compositions and methods of removing prion proteins from the nanoparticle compositions. Methods of using the compositions, as well as kits useful for carrying out the methods are also provided. | 2010-11-25 |
20100297244 | NANODISPERSION - The present invention provides a nanodispersion comprising nanoparticles having a mean size less than 300 nm dispersed in a vehicle comprising a water miscible solvent and water, said nanoparticles comprising one or more taxane derivative, a polymer and a surfactant comprising a mixture of fatty acids or its salts and sterol or its derivatives or its salts. | 2010-11-25 |
20100297245 | METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEIN AND PEPTIDE THERAPEUTIC AGENTS - The present invention provides a pharmaceutical composition formulated for oral delivery, comprising a particulate non-covalently associated mixture of pharmacologically inert silica nanoparticles having a hydrophobic surface, a polysaccharide, and a biologically active protein or peptide suspended in an oil. The present invention further provides methods of manufacturing same and therapeutic methods utilizing same for oral delivery of a therapeutic protein or peptide. | 2010-11-25 |
20100297246 | SILICA-BASED NANOPARTICLES AND METHODS OF STIMULATING BONE FORMATION AND SUPPRESSING BONE RESORPTIOIN THROUGH MODULATION OF NF-KB - Osteoporosis, is an exceedingly common malady that leads to bone fracture and results from an imbalance in the rate of osteoblastic bone formation with respect to osteoclastic bone degradation. Nanotechnology has raised exciting possibilities for the development of novel therapeutic agents. Embodiments of the disclosure provide silica-based fluorescent nanoparticles endowed with natural bone targeting capabilities and expressing potent pro-osteoblastogenic and concomitant anti-osteoclastogenic activities in vitro and the capacity to increase bone mineral density in vivo. Embodiments of the disclosure can achieve their stimulatory effects on osteoblasts, and inhibitory effects on osteoclasts, in part by suppressing NF-κB signal transduction. Embodiments of the present disclosure provide for derivatives of silica-based nanoparticles that represent a novel class of dual anti-catabolic and pro-anabolic agents that may be applicable to the amelioration of numerous osteoporotic conditions. | 2010-11-25 |
20100297247 | Aqueous-Core Lipid Nanocapsules for Encapsulating Hydrophilic and/or Lipophilic Molecules - The invention relates to a composition comprising in an aqueous phase, particles having a diameter in the range of 20 to 500 nm, said particles containing:—an oil phase;—in said oil phase,—an aqueous droplet, or—a nanocapsule (NC) comprising:—an aqueous core, and—a polymeric shell or a shell composed of an amphiphilic substance; and—a surfactant. This composition is particularly useful for encapsulating hydrophilic and/or lipophilic substances. | 2010-11-25 |
20100297248 | ENCAPSULATED PARTICLES FOR AMORPHOUS STABILITY ENHANCEMENT - The present invention provides compositions and methods of making and encapsulating one or more active agents in a chemical vapor deposition layer to enhance the stability. | 2010-11-25 |
20100297249 | ENHANCEMENT OF THE EFFICACY OF THERAPEUTIC PROTEINS - The invention provides a formulation for the administration of at least one therapeutic mammalian protein to a mammal, and for enhancing the absorption, distribution and release of the at least one therapeutic mammalian protein in or on the mammal, the formulation consisting of at least one therapeutic mammalian protein in a micro-emulsion which micro-emulsion is constituted by a dispersion of vesicles or microsponges of a fatty acid based component in an aqueous or other pharmacologically acceptable earner in which nitrous oxide is dissolved, the fatty acid based component comprising at least one long chain fatty acid based substance selected from the group consisting of free fatty acids and derivatives of free fatty acids It further provides a method of the effective delivery of at least one therapeutic mammalian protein to a mammal and for enhancing the therapeutic efficacy of such at least one therapeutic mammalian protein, the method comprising the step of administering the at least one therapeutic mammalian protein to the mammal in such a formulation | 2010-11-25 |
20100297250 | ALKYNES AND METHODS OF REACTING ALKYNES WITH 1,3-DIPOLE-FUNCTIONAL COMPOUNDS - 1,3-Dipole-functional compounds (e.g., azide functional compounds) can be reacted with certain alkynes in a cyclization reaction to form heterocyclic compounds. Useful alkynes (e.g., strained, cyclic alkynes) and methods of making such alkynes are also disclosed. The reaction of 1,3-dipole-functional compounds with alkynes can be used for a wide variety of applications including the immobilization of biomolecules on a substrate. | 2010-11-25 |
20100297251 | ENCAPSULATED PARTICLES FOR ENTERIC RELEASE - The present invention provides a system for delivery of an enteric coated active agent generally resistant to disintegration in an neutral environment having one or more active agents encapsulated by a polymer coating formed by chemical vapor deposition of one or more monomers on the one or more active agents to form a chemical vapor deposition polymer coating that controls the release of the one or more active agents in the gastrointestinal tract. | 2010-11-25 |
20100297252 | NANOPARTICULATE MELOXICAM FORMULATIONS - The present invention is directed to nanoparticulate compositions comprising meloxicam particles having an effective average particle size of less than about 2000 nm. | 2010-11-25 |
20100297253 | TREATMENT OF DIABETES WITH MILK PROTEIN HYDROLYSATE - A milk protein hydrolysate which is preferably caseinoglycomacropeptide and/or a whey protein in a bioavailable form is used for the manufacture of a composition for the treatment or prevention of diabetes or syndrome X. The invention also relates to a method of treatment or prevention of diabetes or syndrome X utilizing such compositions, a method for assessing proglucagon gene expression and GLP-1 release by a cell line derived from an adenocarcinoma of human caecum. | 2010-11-25 |
20100297254 | NUTRACEUTICAL COMPOSITION AND METHODS OF USE - A method of treatment for cartilage degradation in an organism, which includes administering to an organism a composition including a therapeutic amount of an extract from the plant | 2010-11-25 |
20100297255 | MALLEABLE IMPLANTS CONTAINING DEMINERALIZED BONE MATRIX - Described are malleable medical compositions such as pastes or putties that include solids combined with a liquid carrier. The solids include particulate collagen and particulate demineralized bone matrix. The liquid carrier includes an aqueous medium comprising a polysaccharide. Also described are methods for making and using such medical compositions. | 2010-11-25 |
20100297256 | METHODS AND COMPOSITIONS FOR INHIBITING INTEGRINS USING TELLURIUM-CONTAINING COMPOUNDS - Compositions and methods for inhibiting integrin and treating integrin-related conditions, utilizing tellurium-containing compounds, are disclosed. The tellurium-containing compounds comprise at least one tellurium dioxo moiety and may have any one of Formulae I to IV as defined in the specification. Further disclosed are compositions and methods for treating a neoplastic condition characterized by a resistance to an anti-neoplastic agent and by a high level of expression of an integrin by neoplastic cells. | 2010-11-25 |
20100297257 | ANTICOAGULANT ANTAGONIST AND HEMOPHILLIA PROCOAGULANT - A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient. | 2010-11-25 |
20100297258 | Treatment of burns - The invention relates to the treatment of burn injuries. Described are methods for modulating a burn injury in a subject, the method comprising providing the subject with a gene-regulatory peptide or functional analogue thereof, e.g., LQG, AQG, LQGV (SEQ ID NO:1), AQGV (SEQ ID NO:2), LQGA (SEQ ID NO:3), VLPALP (SEQ ID NO:4), ALPALP (SEQ ID NO:5), VAPALP (SEQ ID NO:6), ALPALPQ (SEQ ID NO:7), VLPAAPQ (SEQ ID NO:8), VLPALAQ (SEQ ID NO:9), LAGV (SEQ ID NO:10), VLAALP (SEQ ID NO:11), VLPALA (SEQ ID NO:12), VLPALPQ (SEQ ID NO:13), VLAALPQ (SEQ ID NO:14), VLAPALPA (SEQ ID NO:15), GVLPALP (SEQ ID NO:16), LPGC (SEQ ID NO:17), MTRV (SEQ ID NO:20), MTR, or VVC. Also described is the use of an NF-kappaB down-regulating peptide or functional analogue thereof for the production of a pharmaceutical composition for the treatment of burn injury of a subject. | 2010-11-25 |
20100297259 | PESTICIDE COMPOSITIONS EXHIBITING ENHANCED ACTIVITY - Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide and at least one metal oxide. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one metal oxide. Still, other alternative embodiment pesticide compositions exhibiting enhanced pesticidal activity are disclosed. | 2010-11-25 |
20100297260 | PESTICIDE COMPOSITIONS EXHIBITING ENHANCED ACTIVITY - Pest controlling compositions exhibiting enhanced pesticidal activity levels are disclosed. In one embodiment, a composition includes at least one pesticide, at least one transition metal salt and at least one proteinaceous material. In this embodiment, the composition exhibits enhanced pesticidal activity levels compared to a composition dissimilar only in not having the at least one transition metal salt and the at least one proteinaceous material. | 2010-11-25 |
20100297261 | Food Product and Fortification System Therefor - A food product comprising a source of at least one metal ion selected from Fe and Cu ions and an ascorbic acid derivative substituted in the 2-position, wherein the molar ratio of the metal ion or metal ions in the source of metal ions to the ascorbic acid derivative is from 1:0.5 to 1:15. | 2010-11-25 |
20100297262 | PHARMACEUTICALLY ACTIVE COMPOSITIONS COMPRISING OXIDATIVE STRESS MODULATORS (OSM), NEW CHEMICAL ENTITIES, COMPOSITIONS AND USES - Described herein are pharmaceutical compositions and medicaments, and methods of using such pharmaceutical compositions and medicaments in the treatment of inflammation and cancer. | 2010-11-25 |
20100297263 | COLON CLEANSING COMPOSITIONS AND METHODS - A composition comprising, per litre of aqueous solution, from 30 to 350 g polyethylene glycol, from 3 to 20 g of an ascorbic acid component selected form the group consisting of ascorbic acid, a salt of ascorbic acid, or a mixture thereof, an alkali metal or alkaline earth metal sulphate, preferably from 1 to 15 g thereof, and optionally one or more electrolytes selected from sodium chloride, potassium chloride, and sodium hydrogen carbonate, and preferably also comprising flavourings, is effective in cleansing the gut in preparation for a endoscopy, especially colonoscopy. It is safer than conventional sodium phosphate-based gut cleansing compositions, and hence can be used for patients who would be at risk with sodium phosphate-based compositions, and is better tolerated than conventional PEG-based compositions, leading to better patient compliance and enabling effective out-patient use. | 2010-11-25 |
20100297264 | BOWEL PURGATIVE AND USES THEREOF - The present invention is directed to a dry composition for admixture with water for oral administration to a mammal and methods of using the composition for cleansing the bowel of a mammal in need thereof. | 2010-11-25 |
20100297265 | Optimal compositions and methods for treating oral disease and pain - The present invention generally relates to compositions and methods for oral care. In particular it relates to optimal compositions and methods for treating oral disease and pain where the compositions include cesium and/or rubidium. In a composition aspect, the present invention provides a composition for treating oral disease or oral pain. The composition includes cesium bicarbonate, rubidium bicarbonate, or a mixture of cesium bicarbonate and rubidium bicarbonate at a concentration between 40 mM and 110 mM in an aqueous solution. The composition has a pH between 7.0 and 9.0. | 2010-11-25 |
20100297266 | Preparations and methods for textile and or fiber surface finishing, surface finished articles prepared thereby, and uses therefor - Disclosed are food compositions, comprising aqueous extracts of | 2010-11-25 |
20100297267 | Compositions for diabetes treatment and prophylaxis - Gurmarin containing compositions are useful for modulation of glucose metabolism and the treatment of diabetes. Glucose metabolism in a human patient is regulated by isolated gurmarin-containing dosage forms that optionally contain a non-metabolizable polysaccharide such as the exudate of | 2010-11-25 |
20100297268 | AGENT FOR INCREASING BLOOD ADIPONECTIN QUANTITY - An agent for increasing blood adiponectin quantity is provided, the agent including: a pulverized product or extract of a plant of the genus | 2010-11-25 |
20100297269 | Compositions for intranasal administration - Pharmaceutical compositions are for administration to the nasal tract. In particular, dry powder compositions are cellulose, and in particular hydroxypropylmethylcellulose (HPMC), and one or more therapeutic agents. It has been shown that administration of HPMC to the nasal cavity is capable of enhancing natural mucus. These powders, and the gel that forms when they are administered to the nasal tract, have now surprisingly been found to be a very effective way of intranasally administering therapeutic agents, and in particular, herbal or homeopathic agents. | 2010-11-25 |
20100297271 | COMPOSITIONS AND METHODS FOR REDUCING HEPATOTOXICITY ASSOCIATED WITH DRUG ADMINISTRATION - The present invention relates to the discovery that acetylsalicylic acid (ASA or aspirin), salicylic acid (SA) and related salicylate esters and their pharmaceutically acceptable salts, when coadministered in effective amounts with a drug or other bioactive agent which typically (in the absence of the salicylate compound) produces significant hepatotoxicity as a secondary indication, will substantially reduce or even eliminate such hepatotoxicity. Favorable therapeutic intervention results from the use of the present invention having the effect of reducing hepatotoxicity associated with the administration of certain drugs and other bioactive agents and in certain instances of allowing the administration of higher doses of a compound which, without the coadministration, would produce hepatotoxicity which limits or even negates the therapeutic value of the compound. | 2010-11-25 |
20100297272 | Cosmetic Composition Containing Lingonberry Extract and Its Uses - The invention relates to a cosmetic composition containing lingonberry extract and its use on skin cosmetology thereof. The present invention has provided a lingonberry extract wherein containing polyphenols components including anthocyanidin, procyanidin, resveratrol, catechin and so on. The present invention also relates to the application of lingonberry extract on skin cosmetology, including without limitation whitening, diminishing visible pigmentation, anti-wrinkle, moisturizing, smoothing and improving skin sensitivity. The invention also has revealed drugs, cosmetic composition and food prepared by using lingonberry extract. Comparing with the prior art cosmetic compositions, the said lingonberry extract of the present invention has higher effects and safe. | 2010-11-25 |
20100297273 | EMULSIFIED WAX COMPOSITIONS AND USES THEREOF - The present invention discloses emulsified wax compositions having a wide range of uses, including as cosmetic, pharmaceutical and agricultural compositions, particularly for improving skin moisture, appearance, and wound healing, for the treatment of inflammation and allergic responses of the skin, and for preservation of agricultural fresh produce. The composition of the invention comprises an aqueous phase and at least one wax at a concentration of at least 5%, at least one fatty acid and at least one basic amino acid or a salt thereof. | 2010-11-25 |
20100297274 | COCOA EXTRACTS FOR USE IN PROVIDING SKIN BENEFITS - A cocoa extract obtainable by the extraction of non-defatted cocoa beans which have not been fermented or have been allowed to ferment for no more than three days, having a polyphenol content of more than 25% by weight, may be used to provide skin benefits by oral administration. | 2010-11-25 |
20100297275 | Positioning device - The present invention concerns a system for the aftertreatment of parisons ( | 2010-11-25 |
20100297276 | Spacer Mold and Methods Therefor - A hip spacer mold forming a spacer with a spacer stem connected to a spacer head has a stem portion for forming a spacer stem. The hip spacer mold also has a plurality of interchangeable head modules configured for alternatively forming spacer heads of a plurality of different predetermined sizes. The head modules are configured to be disposed adjacent the stem portion. | 2010-11-25 |
20100297277 | Extrusion Device - An extrusion device comprising an extruder screw for conveying extrudable material, in particular natural or synthetic rubber materials. The extrusion device also comprises a nozzle having two nozzle dies that are displaceable relative to one another. Furthermore, the extrusion device comprises a reinforcing material feeder for conveying reinforcing material in the direction of the nozzle, via which reinforcing material and extrudable material are discharged together from the extrusion device. The reinforcing material is guided in a horizontal plane of separation. | 2010-11-25 |
20100297278 | STRAND PELLETIZER - The invention relates to a device for pelletizing at least one strand ( | 2010-11-25 |
20100297279 | EXTENDED NIP EMBOSSING APPARATUS - An apparatus for embossing a web substrate is disclosed. The apparatus has first, second, and third pattern rolls. The first, second, and third patterns rolls each have respective first, second, and third pluralities of raised elements and recesses disposed thereon. A first nip is formed between the first and second pattern rolls and a third nip is formed between the first and third pattern rolls. The raised elements and the recesses of the first pattern roll are matingly engagable with the corresponding plurality of raised elements and recesses of the corresponding second and third pattern rolls. The first and second nips are both adapted to receive the web substrate and emboss the web substrate with the respective and corresponding embossing patterns when the web substrate is disposed within the respective nip. | 2010-11-25 |
20100297280 | EXTENDED NIP EMBOSSING APPARATUS - An apparatus for embossing a web substrate is disclosed. The apparatus has a pattern roll, at least two rolls juxtaposed in an axially parallel relationship with the pattern roll, and a continuous belt disposed about the at least two rolls. The pattern roll has a circumference and an embossing pattern disposed upon a surface thereof. The continuous belt has a circumferential axis generally corresponding to the surface of said pattern roll. The continuous belt is disposed upon at least a portion of the circumference of the pattern roll and forms a circumferentially elongate nip therebetween. The pattern roll and the continuous belt are adapted to receive the web substrate at the elongate nip. The pattern roll and the continuous belt emboss the web substrate while the web substrate is disposed between the pattern roll and the continuous belt. | 2010-11-25 |
20100297281 | EXTENDED NIP EMBOSSING APPARATUS - An apparatus for embossing a web substrate is disclosed. The apparatus has a pattern roll, at least two rolls juxtaposed in an axially parallel relationship with the pattern roll, and a continuous belt disposed about the at least two rolls. The pattern roll has a circumference and an embossing pattern disposed upon a surface thereof. The continuous belt is capable of providing a compressive force to the surface of the pattern roll and has a circumferential axis generally corresponding to the surface of the pattern roll. The continuous belt is disposed proximate to at least a portion of the circumference of the pattern roll and forms a circumferentially elongate nip therebetween. The pattern roll and the continuous belt are adapted to receive the web substrate at the elongate nip. | 2010-11-25 |
20100297282 | IMPRINT LITHOGRAPHY APPARATUS - An arrangement suitable for use in an imprint lithography apparatus is disclosed. The arrangement includes a support structure arranged to support an imprint template arrangement, a first actuator configured to apply a force to the imprint template arrangement, and a second actuator attached to the support structure, and arranged in use to extend between the support structure and the imprint template arrangement, the second actuator configured to apply a force to the imprint template arrangement, a range of movement of the second actuator being greater than a range of movement of the first actuator. | 2010-11-25 |
20100297283 | INJECTION NOZZLE, IN PARTICULAR HOT-RUNNER NOZZLE, FOR ARRANGEMENT IN AN INJECTION MOULD - In the case of an injection nozzle, in particular hot-runner nozzle ( | 2010-11-25 |
20100297284 | CASTING MOLD DEVICE - A metal mold device for casting that is adapted to prevent a casting sleeve from falling and that keeps even spacing between an inner circumferential wall of the casting sleeve and an outer circumferential wall of a bore pin. Ball plungers are provided at regular intervals in a circumferential direction on an outer circumferential portion of the bore pin in the vicinity of a distal end of the bore pin and on an outer circumferential portion in the vicinity of a basal end thereof, respectively, with respect to the axial direction of the bore pin. Three distal ball plungers are provided on the outer circumferential portion in the vicinity of the distal end of the bore pin and three basal ball plungers are provided on the outer circumferential portion in the vicinity of the basal end thereof. The distal ball plungers are 60° out of phase with the basal ball plungers when viewed in the axial direction. Further, the distal ball plungers are provided in an area where a piston ring, in the vicinity of a top dead center position of a piston, is located. | 2010-11-25 |
20100297285 | Pipe Body Extrusion Device - A pipe body extrusion device includes a fixed unit, a holding bracket, a packing bolt, a drive unit, a pipe expanded and molded piece, a clip unit, and an operating unit; in which the holding bracket is for clipping a round pipe and putting into a holding space of the fixed unit, the packing bolt is locked into the fixed unit and then the holding bracket is clipped to be positioned, the drive unit is screwed and locked at the fixed unit including a drive rod, the pipe expanded and molded piece is installed at the drive rod and through the clip unit for rapidly integrating or disconnecting with the drive rod, and the operating unit is for driving the drive rod for leading the pipe expanded and molded piece near or away from the round pipe; thus, the present invention has the features of integral structure, simple operation, and enhancing operational efficiency. | 2010-11-25 |
20100297286 | HIGH PRESSURE EMBOSSING APPARATUS - An apparatus for embossing a web substrate is disclosed. The apparatus has a pattern roll having an embossing pattern disposed thereon, an anvil roll juxtaposed in an axially parallel relationship with the pattern roll, and an embossing roll juxtaposed in an axially parallel relationship with said pattern roll. The anvil roll has a hardness of less than about 40 P&J. The embossing roll has a hardness of greater than about 40 P&J. | 2010-11-25 |
20100297287 | Mould cavity with decoupled cooling-channel routing - A cavity member for a mold cavity structure for the production of hollow body moldings, wherein the cavity member has a substantially hollow-cylindrical element, wherein a cooling passage is provided at the outside of the hollow-cylindrical element. To provide a cavity member which is simple to manufacture and which permits more effective cooling of the cavity member it is proposed in accordance with the invention that there are provided one or more guide elements for forming the cooling passage, wherein the guide elements and the hollow-cylindrical element are in the form of separate parts. | 2010-11-25 |
20100297288 | PACKAGING OF A STACK OF CONFECTIONERY PELLETS AND THE LIKE - Packaging of a stack of confectionery pellets ( | 2010-11-25 |
20100297289 | Composition for Stabilising a Dietary Aqueous Liquid Sensitive to Oxidation - The present invention relates to a composition for protecting from oxidation a dietary liquid, which contains substances sensitive to oxidation during the shelf-life thereof including a combination of two types of yeast cells:
| 2010-11-25 |
20100297290 | ALTERNATIVE METHOD FOR RUM PRODUCTION REDUCING POLLUTION AND BYPASSING UPGRADE OF POLLUTION CONTROLS - A method and process for producing a high quality, high-end ethanol product from a lower quality, low-end ethanol product. The method and process can eliminate or reduce waste disposal costs for a distillery constrained by its location from employing an acceptable, cost-effective waste disposal method. | 2010-11-25 |
20100297291 | VISIBLE/NEAR-INFRARED SPECTRUM ANALYZING METHOD AND GRAPE FERMENTING METHOD - A visible/near-infrared spectrum analyzing method for identifying components of a sample and determining characteristics of the components using visible light and/or near-infrared light having a wavelength of 400 to 2500 nm. The quantitative determination of the components, which have been conventionally hard to identify, of a grape of a small fruit cultivar for wine making can be made in a nondestructive way. A grape of a small fruit cultivar for wine making (a sample under examination) is irradiated with visible light and/or near-infrared light having a wavelength of 600 to 1100 nm and is subjected to spectrum determination of the sample and an absorption spectrum is determined from the obtained spectrum. By employing a multivariate statistical analysis (hereinafter referred to multivariate analysis) by the PLS or MLR method, a model enabling quantitative determination of the components of the sample under examination is created. | 2010-11-25 |
20100297292 | Reduced Pigmentation Microalgae Strains and Products Therefrom - The invention provides unique and novel strains of microalgae that have been subjected to non-transgenic methods of mutation sufficient to reduce the coloration of biomass produced by the strains. Biomass produced from such strains can be used in the manufacture of baked goods, gluten free foods, beverages, high lipid algal flours, and other foods. Pigments such as carotenoids and chlorophyll can be undesirable for consumer acceptance when incorporated into foods such as mayonnaise, yogurt, and white sauces that are not traditionally associated with colors such as yellow, red, orange and green. Some pigments, such as chlorophyll, can also create undesirable taste profiles. Use of reduced pigment microalgal biomass expands the range of food products that can be manufactured with healthy lipid profiles. High protein containing biomass of the invention, also reduced in pigmentation, is also incorporated into products such as meat analogues, nutritional bars and meal replacement beverages. The reduced pigmentation microalgae also allow for incorporation of higher amounts of biomass into certain food products that could otherwise be achieved using highly pigmented microalgal biomass. Methods of generating novel reduced pigment microalgae are disclosed herein. The strains provided by the invention are also useful in the manufacture of healthy, neutral colored extracted triglyceride oils. | 2010-11-25 |
20100297293 | METHOD FOR REDUCING THE SATURATED FATTY ACID CONTENT OF MILK FAT, PRODUCTS OBTAINED AND APPLICATIONS THEREOF - The present invention is related to a method for reducing the saturated fatty acid content of milk fat, a milk fat which includes reduced saturated fatty acid content, preferably obtained by the method of the invention, as well as to food compositions comprising said fat. | 2010-11-25 |
20100297294 | Yogurt Compositions and Methods of Making - The invention relates to food products and to their methods of preparation. More particularly, the invention relates to cultured dairy products, especially cultured yogurt products and to their methods of preparation. | 2010-11-25 |
20100297295 | Microalgae-Based Beverages - The invention provides novel beverages and raw materials for the manufacture thereof, such beverage and raw materials containing microalgae of various species with varying components. Attributes of the microalgal biomass used in the invention include nutrition-providing materials such as carotenoids, dietary fiber, tocotrienols and tocopherols, and varying lipid compositions, particularly low levels of saturated lipids. Attributes of the microalgal biomass used in the invention include structural attributes such as improved mouth feel compared to alternative milk products such as soy milk and rice milk. The novel beverages provide delivery systems for high nutrition materials found in microalgae. The invention provides a new category of finished beverages based on microalgae (such as refrigerated and shelf stable liquids and emulsions) as well as compositions for augmenting properties of current beverages through inclusion of novel microalgae-based materials as ingredients. | 2010-11-25 |
20100297296 | Healthier Baked Goods Containing Microalgae - Provided herein are microalgae-containing baked goods with novel properties compared to preexisting products of the same type. Methods of formulating and manufacturing these foods to deliver reduced fat, reduced cholesterol, and increased fiber content are disclosed herein. Various embodiments include elimination or reduction of eggs, butter, animal fat, and saturated oils in favor of healthy oil-containing microalgae biomass and oils, including the manufacture of foods with lower calories than preexisting products of the same type. Methods of producing raw materials for the manufacture of novel processed baked foods and intermediates such as cake and bead mixes are also provided. | 2010-11-25 |
20100297297 | ENERGY BEVERAGES AND METHODS FOR FABRICATION THEREOF - Powder composition for preparing an energy beverage are provided, the powder compositions including at least one vitamin of group B, chromium picolinate, and calcium carbonate, and optionally also including other vitamins, minerals, or nutrient, such as vitamins A, C, and/or E. The beverage is designed as means of providing additional energy to persons suffering from diabetes. Methods for preparing such a powdered composition and energy beverage are also provided. | 2010-11-25 |
20100297298 | MEAL REPLACEMENT BEVERAGE - Meal replacement compositions are described herein. The meal replacement compositions are made using all natural ingredients and includes relatively high amounts of fiber and protein and relatively low amounts of fat. In some instances, a single serving of a meal replacement composition includes high amounts of cocoa, an ingredient containing plant polyphenols. | 2010-11-25 |